Value

How should drug prices be specified in U.S. economic analyses?

How have new medicines improved health and life expectancy in the United States?

Leading with research: J&J Center publishes evidence for the future of health policy

Tailoring generalized cost-effectiveness analysis (GCEA) to the U.S. setting: The importance of using the right prices

U.S. value assessments need to reflect actual prices and how they change over time

Are state prescription drug affordability boards (PDABs) and upper payment limits (UPLs) achieving their intended goals?

Are cost-effectiveness analysis thresholds fit for purpose for U.S. decision-making?